TrivarX Raises $3.5M to Advance Stabl-Im MRI Brain Tumour Technology
TrivarX has received $3.5 million in second-tranche placement funding, enabling advancement of its innovative Stabl-Im technology for early, non-invasive brain tumour detection. The funding supports manufacturing scale-up and regulatory preparations ahead of a planned Phase 1 clinical trial in 2026.
- Received $3.5 million second-tranche placement funding
- Advancing Stabl-Im stable isotope MRI technology for brain tumour detection
- Funding allocated to manufacturing scale-up and regulatory pre-submission
- Phase 1 clinical trial planned for calendar year 2026
- Technology offers radiation-free, non-invasive imaging with potential clinical advantages
Funding Boosts Clinical Ambitions
TrivarX Limited (ASX, TRI) has announced receipt of $3.5 million from the second tranche of its strategic placement, significantly strengthening its financial position. This capital injection is earmarked to accelerate the development of Stabl-Im, a novel imaging platform designed to detect brain tumours early and safely without the use of radiation or invasive procedures.
Innovating Brain Tumour Detection
Stabl-Im leverages stable isotope labelling combined with standard MRI technology to identify replicating tumour cells in the brain. Unlike conventional MRI scans that primarily reveal anatomical changes, Stabl-Im targets cellular replication; a hallmark of tumour growth; offering a functional imaging approach. This method promises to overcome limitations of current diagnostic tools, such as PET scans, which involve radiation exposure and have limited sensitivity for small lesions.
Pathway to Clinical Validation
The new funding will support critical preparatory activities including manufacturing scale-up of the stable isotope compounds, quality control validation, and regulatory pre-submission engagements in the US and European Union. These steps are essential to ensure compliance and smooth progression into clinical trials. TrivarX plans to initiate a first-in-human Phase 1 clinical trial in 2026, focusing on safety, imaging precision, and reproducibility in patients with confirmed brain tumours.
Strategic and Regulatory Considerations
TrivarX is supported by experienced regulatory and medical consultants, alongside Dr Daniel Tillett, the technology’s inventor and a respected figure in oncology biotech. The company is targeting orphan drug designation, which could provide market exclusivity and expedite regulatory pathways given the high unmet need in brain metastases diagnostics. The trial design aims for efficient recruitment and rapid data generation, potentially accelerating broader clinical adoption.
Market Potential and Future Outlook
The global diagnostic imaging market exceeds US$600 billion, with MRI representing a fast-growing segment driven by oncology and neurology applications. Stabl-Im’s ability to safely and repeatedly image metabolically active tumours could disrupt current standards of care, enabling earlier intervention and improved patient outcomes. As TrivarX advances through clinical milestones, investors and clinicians alike will watch closely to see if this technology can fulfill its promise.
Bottom Line?
TrivarX’s latest funding milestone sets the stage for pivotal clinical trials that could redefine brain tumour imaging and patient care.
Questions in the middle?
- What will Phase 1 trial data reveal about Stabl-Im’s safety and imaging accuracy in humans?
- How will regulatory agencies in the US and EU respond to this novel imaging approach?
- What commercial partnerships or collaborations might TrivarX pursue to scale Stabl-Im globally?
